Bluejay Diagnostics (NASDAQ:BJDX) CEO Indranil Dey Purchases 12,500 Shares

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) CEO Indranil Dey acquired 12,500 shares of the business’s stock in a transaction on Saturday, March 14th. The stock was purchased at an average cost of $2.00 per share, with a total value of $25,000.00. Following the acquisition, the chief executive officer directly owned 12,501 shares of the company’s stock, valued at $25,002. This represents a 1,250,000.00% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Bluejay Diagnostics Stock Performance

BJDX opened at $1.72 on Tuesday. Bluejay Diagnostics, Inc. has a fifty-two week low of $1.63 and a fifty-two week high of $16.68. The company has a fifty day moving average of $1.90 and a two-hundred day moving average of $3.19. The stock has a market capitalization of $1.78 million, a price-to-earnings ratio of -0.15 and a beta of 0.72.

Bluejay Diagnostics (NASDAQ:BJDX) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.95) earnings per share for the quarter.

Institutional Trading of Bluejay Diagnostics

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC bought a new stake in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned 9.15% of Bluejay Diagnostics as of its most recent SEC filing. Hedge funds and other institutional investors own 18.47% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Bluejay Diagnostics has an average rating of “Sell”.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.